8-KLeadership ChangesShareholder Matters

Johnson Controls International plc 8-K Report, Executive Changes (Mar 14, 2025)

Filed March 14, 2025For Securities:JCI

Summary

Johnson Controls International plc (JCI) filed an 8-K report on March 13, 2025, detailing key outcomes from its Annual General Meeting (AGM) held on March 12, 2025. The most significant event was the official transition of leadership, with Joakim Weidemanis succeeding George Oliver as Chief Executive Officer, effective immediately after the AGM. Mr. Oliver, who was re-elected as a director, will continue to serve as Chairman of the Board until his planned retirement on July 31, 2025. The Board also approved an increase in its size to thirteen members, with Mr. Weidemanis appointed as a director. Shareholders at the AGM also voted on and approved several management proposals. These include the ratification of PricewaterhouseCoopers LLP as the independent auditor, authorization for the Audit Committee to set auditor remuneration, and approval for the company to conduct market purchases of its shares and to determine the reissuance price range for treasury shares. Additionally, advisory votes on executive compensation, the Board's authority to allot shares, and the waiver of statutory pre-emption rights were all approved by shareholders. These resolutions indicate shareholder support for the company's governance and capital management strategies.

Key Highlights

  • 1Joakim Weidemanis officially succeeded George Oliver as CEO of Johnson Controls International plc, effective March 12, 2025.
  • 2George Oliver, former CEO, was re-elected as a director and will remain Chairman of the Board until July 31, 2025.
  • 3The Board of Directors was expanded to thirteen members, with Joakim Weidemanis appointed as a new director.
  • 4Shareholders overwhelmingly approved the ratification of PricewaterhouseCoopers LLP as the independent auditor.
  • 5Shareholder approval was granted for JCI to conduct market purchases of its own shares.
  • 6Key governance proposals, including executive compensation and the Board's authority to allot shares, received shareholder approval.
  • 7Shareholders approved the waiver of statutory pre-emption rights for certain share issuances.

Frequently Asked Questions